Roche has announced the inauguration of the new research home for the Institute of Human Biology (IHB). The opening marks a significant milestone in Roche’s strategy to unlock the transformative potential of human model systems to revolutionise the future of drug discovery and development.
IHB leverages human disease biology, computational biology and translational bioengineering to pioneer advanced systems that replicate human disease biology with unprecedented precision. Bringing this diverse expertise together across multidisciplinary projects allows scientists the chance to generate sophisticated models, such as complex cultured tissue samples, organoids, microfluidic 'organ-on-chip' technologies and in silico modelling. These models are deepening our understanding of the fundamental mechanisms of human disease and therapeutics and transform the future of R&D.
Building 92 will house up to 250 researchers and provide a collaborative environment designed to bridge the gap between fundamental and industry sciences. It includes modular laboratories that will allow sustainable growth and foster interdisciplinary exchange.
Roche is currently investing CHF 1.4 billion in the site development in Basel & Kaiseraugst. Since 2016, Roche has invested approximately CHF 7 billion into its Swiss sites. Furthermore, Roche has invested CHF 33 billion in research and development in Switzerland since 2016, resulting in a total investment of around CHF 41 billion over the last decade (2016 to 2025).
